Abstract
As a target for gene therapy, Duchenne muscular dystrophy (DMD) presents many obstacles but also an unparalleled prospect for correction by alternative splicing. The majority of mutations in the dystrophin gene occur in the region encoding the spectrin-like central rod domain, which is largely dispensable. Thus, splicing around mutations can generate a shortened but in-frame transcript, permitting translation of a partially functional dystrophin protein. We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining a potent transfection protocol with a 2-O-methylated phosphorothioated antisense oligoribonucleotide (2OMeAO) designed to promote skipping of the mutated exon*. The treated mice show persistent production of dystrophin at normal levels in large numbers of muscle fibers and show functional improvement of the treated muscle. Repeated administration enhances dystrophin expression without eliciting immune responses. Our data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy.
*NOTE: In the version of this article initially published online, the following errors appeared: The fourth sentence of the abstract was incorrect. It has been changed to, "We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining…to promote skipping of the mutated exon." The sixth sentence of the first paragraph of the Results was incorrect and has been changed. It now reads, "…(C57Bl/10ScSn; designated C57)…" Figure 2 and its legend contained an error. The figure should be labeled with subpanels a and b. The legend should read, "Figure 2 Detection of dystrophin and dystrophin protein complexes. Exon mapping of 2OMeAO-induced dystrophin (a,b) and detection of dystrophin protein complexes (b) in serial sections..." These mistakes have been corrected for the HTML and print versions of the article.
Similar content being viewed by others
Change history
16 July 2003
The full text and PDF were updated as per note
Notes
NOTE: In the version of this article initially published online, the following errors appeared: The fourth sentence of the abstract was incorrect. It has been changed to, "We have tested this idea in vivo in the mdx dystrophic mouse (carrying a mutation in exon 23 of the dystrophin gene) by combining…to promote skipping of the mutated exon." The sixth sentence of the first paragraph of the Results was incorrect and has been changed. It now reads, "…(C57Bl/10ScSn; designated C57)…" Figure 2 and its legend contained an error. The figure should be labeled with subpanels a and b. The legend should read, "Figure 2 Detection of dystrophin and dystrophin protein complexes. Exon mapping of 2OMeAO-induced dystrophin (a,b) and detection of dystrophin protein complexes (b) in serial sections..." These mistakes have been corrected for the HTML and print versions of the article.
References
Hoffman, E.P., Brown, R.H. Jr. & Kunkel, L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919–928 (1987).
Laing, N.G. Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy. in Molecular and Cell Biology of Muscular Dystrophy (ed. Partridge, T.) 37–84 (Chapman & Hall, London, 1993).
Beauchamp, J.R., Morgan, J.E., Pagel, C.N. & Partridge, T.A. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J. Cell. Biol. 144, 1113–1122 (1999).
Liu, F., Nishikawa, M., Clemens, P.R. & Huang, L. Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Mol. Ther. 4, 45–51 (2001).
Yuasa, K. et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9, 1576–1588 (2002).
Wang, B., Li, J. & Xiao, X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA. 97, 13714–13719 (2000).
Monaco, A.P. et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90–95 (1988).
Mann, C.J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA. 98, 42–47 (2001).
Dickson, G., Hill, V. & Graham I.R. Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul. Disord. 12 (suppl. 1), S67–S70 (2002).
Aartsma-Rus, A. et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (suppl. 1), S71–S77 (2002).
Lu, Q.L., Bou-Gharios, G. & Partridge, T.A. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 10, 131–142 (2003).
Lu, Q.L. et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. 148, 985–996 (2000).
Watchko, J. et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451–1460 (2002).
Rando, T.A., Disatnik, M.H. & Zhou, L.Z. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc. Natl. Acad. Sci. USA 97, 5363–5368 (2000).
Wagner, K.R. et al. Gentamycin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706–711 (2001).
England, S.B. et al. Very mild muscular dystrophy associated with deletion of 40% dystrophin. Nature 343, 180–182 (1990).
Sherratt, T.G. et al. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am. J. Hum. Genet. 53, 1007–1015 (1993).
Wilton, S.D. et al. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul. Disord. 7, 329–335 (1997).
Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90, 8673–8677 (1993).
De Angelis, F.G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48–50 DMD cells. Proc. Natl. Acad. Sci. USA 99, 9456–9461 (2002).
Mann, C.J. et al. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. 4, 644–654 (2002).
Sazani, P. et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228–1233 (2002).
Lu, Q.L. & Partridge, T.A. A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J. Histochem. Cytochem. 46, 977–984 (1998).
Lu, Q.L., Liang, H.D., Partridge, T. & Blomley, M.J. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 10, 396–405 (2003).
Lou, F., Curtin, N.A. & Woledge, R.C. Isometric and isovelocity contractile performance of red muscle fibres from the dogfish Scyliorhinus canicula. J. Exp. Biol. 205, 1585–1595 (2002).
Lynch, G.S. et al. Force and power output of fast and slow skeletal muscles from mdx mice 6–28 months old. J. Physiol. 535, 591–600 (2001).
Acknowledgements
This work was supported by the Medical Research Council of Great Britain, the Muscular Dystrophy Group of Great Britain, the Leopold Muller Foundation, the Muscular Dystrophy Association of the USA and Western Australia, the Neuromuscular Foundation of Western Australia, and the National Health & Medical Research Council of Australia. We also thank R.C. Woledge (Institute of Human Performance, University College London) and A. Wilson (Structure and Motion Laboratory, Royal Veterinary College, London) for providing equipment for part of the muscle contraction tests.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lu, Q., Mann, C., Lou, F. et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9, 1009–1014 (2003). https://doi.org/10.1038/nm897
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm897
- Springer Nature America, Inc.
This article is cited by
-
Duchenne muscular dystrophy trajectory in R-DMDdel52 preclinical rat model identifies COMP as biomarker of fibrosis
Acta Neuropathologica Communications (2022)
-
Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders
Drugs (2020)
-
Gene therapies in canine models for Duchenne muscular dystrophy
Human Genetics (2019)